Cue Health Launches Cue Care™ Nationwide to Provide Same-Day, At-Home, Test-to-Treatment Service for COVID-19
- Consult virtually and on-demand with a healthcare professional about their test result;
- Obtain an e-prescription - if medically indicated - for a medication to treat the virus; and
- Get the medication delivered - usually within hours* - conveniently and safely at home or the medication will be made available for pickup at their local pharmacy.
Within a few weeks,
"Early diagnosis and treatment have shown to lead to better health outcomes, which is why we're proud to deliver timely testing and treatment all within the Cue Health App," said
Current and future testing capabilities
While Cue Care is for COVID-19 patients today, it is expected to apply to a wide range of diagnostic tests in Cue's pipeline, particularly those for which specific treatments are available. For example, if an individual tests positive for flu, they will be able to use Cue Care to connect with a healthcare professional and, if eligible, get an antiviral for flu delivered to them on the same day, all within the Cue Health App. Cue Care is expected to handle other respiratory infections, such as strep throat and respiratory syncytial virus (RSV), as well as sexually transmitted infections, such as chlamydia and gonorrhea.
Cue has the most accurate at-home COVID-19 test**, delivering results in 20 minutes to connected mobile devices. It detects all known COVID-19 variants of concern in people with or without symptoms. Cue is used in homes, in point-of-care settings, and by world-class organizations across the country, including
* Antiviral medications prescribed by independent healthcare professionals through Cue Care are subject to availability and patient eligibility.
** #1 accuracy claim based on comparison of clinical study results submitted to the
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements". The words, without limitation, "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these or similar identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including those related to the expected future diagnostic test menu and the factors discussed in the "Risk Factors" section of Cue's Annual Report on Form 10-K for the year ended
Cue's COVID-19 tests have not been FDA cleared or approved; but have been authorized by FDA and under an Emergency Use Authorization (EUA). These products have been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens. The emergency use of these products is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.
View original content to download multimedia:https://www.prnewswire.com/news-releases/cue-health-launches-cue-care-nationwide-to-provide-same-day-at-home-test-to-treatment-service-for-covid-19-301613695.html
MEDIA INQUIRIES: firstname.lastname@example.org